Sentinel Node Mapping in Penile Cancer: An Update on Methods and Pitfalls

Review argues current DSNB guidelines trigger full lymph node dissection in over 80% of men who wouldn't benefit from it

Journal: Seminars in Nuclear Medicine | Published: 2025-11-20 | Type: Review | PMID: 41271547 Authors: Christian Arvei Moen (Haukeland University Hospital, Bergen, Norway); Jakob Kristian Jakobsen (Aarhus University Hospital, Aarhus, Denmark) Funding/COI: Moen holds a 50% research position funded by Helse Bergen HF. Jakobsen has a Novo Nordisk Foundation research grant, travel support from Medac, a sponsored research agreement with Medac, and has done consultancy for Cystotech. Neither of those industry relationships is directly relevant to DSNB tracers, but they should be noted.

Summary

Dynamic sentinel node biopsy (DSNB) is the current gold standard for staging clinically node-negative penile cancer, where up to 25% of patients harbor hidden inguinal metastases that noninvasive imaging consistently misses. The procedure carries a false-negative rate of roughly 12–13%, which varies by center — a gap the authors attribute to lack of standardization across institutions. The review's sharpest observation is arithmetical: fewer than 20% of men with positive sentinel nodes turn out to have additional metastatic disease after full inguinal lymph node dissection (ILND), meaning current guidelines likely overtreating more than 80% of that group with a morbid surgery.

Claims

• Up to 20–25% of cN0 penile cancer patients have occult inguinal metastases
• DSNB average false-negative rate: ~12–13%, with inter-center variation attributed to technique differences
• Noninvasive imaging currently lacks sufficient accuracy for nodal staging in this population
• Fewer than 20% of patients with metastatic sentinel nodes have additional metastases found at subsequent ILND — implying >80% of those who proceed to ILND derive no staging benefit from it
• Magnetic nanoparticles and circulating tumour DNA (ctDNA) analysis are identified as emerging alternatives to radioactive tracers
• Intraoperative frozen section analysis of sentinel nodes can enable same-session radical ILND when metastases are detected

Study Quality

This is a narrative review, not a systematic review or meta-analysis. No PRISMA flow chart, no explicit inclusion/exclusion criteria for the studies cited, no pooled analysis. The 12–13% false-negative figure and the ">80% overtreatment" estimate are presented as established facts derived from the literature, but the review does not meta-analytically derive them here — readers should trace those numbers to the primary sources before treating them as settled.

The value of the paper lies in clinical synthesis from two experienced European urology groups, not in new data generation. For a rare cancer where randomized trials are functionally impossible to power, narrative expert review is a legitimate format — but it carries the usual risks of selective citation and unstated priors.

Red Flags

• Narrative review only — no systematic methodology, no PROSPERO registration mentioned, no explicit search strategy
• Jakobsen's sponsored research agreement and consultancy with device companies (Medac, Cystotech) create potential bias toward technology-forward framing, even if not directly about DSNB tracers
• The >80% overtreatment claim is attention-grabbing but derives from a single arithmetic inference (fewer than 20% of DSNB-positive patients have additional disease at ILND); the clinical question of whether ILND still benefits that minority is not resolved here
• Penile cancer is rare; the literature base is dominated by single-center series from a handful of high-volume European institutions, which limits generalizability
• "Funding: Not listed" for the review itself while one author has multiple active industry relationships

Strengths

• Rare cancer, sparse primary literature — a current synthesis from active practitioners has genuine clinical utility
• Honestly quantifies the overtreatment problem rather than defending the status quo
• Covers the full procedural workflow, including the underreported problem of radiotracer-silent groins
• Flags emerging alternatives (magnetic nanoparticles, ctDNA) with appropriate hedging rather than overstating readiness

Verdict

Worth reading for the overtreatment calculus alone: if the numbers hold up, the current standard sends more than four out of five DSNB-positive men through a morbid lymph node dissection that finds nothing. That's a hypothesis worth testing rigorously, and this review at least names it clearly. As a standalone paper, it's a useful orientation to an underpowered field — but treat its cited figures as pointers to primary sources, not as meta-analytic conclusions. Jakobsen's industry ties don't invalidate the review, but they warrant scrutiny when the paper advocates for technology adoption.